Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature
We report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of these patients. Clinical data, laboratory result...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Gastrointestinal Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/9462942 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554171910324224 |
|---|---|
| author | Matthew H. Kemm Cory D. Manly Thanh D. Hoang Vinh Q. Mai Mohamed K. M. Shakir |
| author_facet | Matthew H. Kemm Cory D. Manly Thanh D. Hoang Vinh Q. Mai Mohamed K. M. Shakir |
| author_sort | Matthew H. Kemm |
| collection | DOAJ |
| description | We report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of these patients. Clinical data, laboratory results, and imaging were reviewed. A literature search was performed in PUBMED using combinations of the terms “multiple endocrine neoplasia type 1,” “somatostatin,” octreotide,” “pancreatic polypeptide,” and “pancreatic tumor.” Relevant references were selected and reviewed. A 43-year-old male with a history of MEN1 and multiple subcentimeter neuroendocrine tumors with elevation of PP was treated with octreotide therapy leading to a reduction and normalization of PP levels. The patient tolerated octreotide therapy but self-discontinued octreotide after 24 months with a rise in PP levels off therapy. Tumors remained stable in size through 40 months of imaging follow-up. In patients with MEN1 and subcentimeter pNETs, octreotide therapy is well tolerated and can lead to a significant drop in PP levels with no change in lesion size. There is insufficient data to suggest long-term benefit with octreotide therapy but it may be considered versus standard conservative management. |
| format | Article |
| id | doaj-art-b87904097be64329b0a724b7e37ec869 |
| institution | Kabale University |
| issn | 2090-6528 2090-6536 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Gastrointestinal Medicine |
| spelling | doaj-art-b87904097be64329b0a724b7e37ec8692025-02-03T05:52:11ZengWileyCase Reports in Gastrointestinal Medicine2090-65282090-65362019-01-01201910.1155/2019/94629429462942Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the LiteratureMatthew H. Kemm0Cory D. Manly1Thanh D. Hoang2Vinh Q. Mai3Mohamed K. M. Shakir4Division of Endocrinology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, USADivision of Endocrinology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, USADivision of Endocrinology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, USADivision of Endocrinology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, USADivision of Endocrinology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, USAWe report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of these patients. Clinical data, laboratory results, and imaging were reviewed. A literature search was performed in PUBMED using combinations of the terms “multiple endocrine neoplasia type 1,” “somatostatin,” octreotide,” “pancreatic polypeptide,” and “pancreatic tumor.” Relevant references were selected and reviewed. A 43-year-old male with a history of MEN1 and multiple subcentimeter neuroendocrine tumors with elevation of PP was treated with octreotide therapy leading to a reduction and normalization of PP levels. The patient tolerated octreotide therapy but self-discontinued octreotide after 24 months with a rise in PP levels off therapy. Tumors remained stable in size through 40 months of imaging follow-up. In patients with MEN1 and subcentimeter pNETs, octreotide therapy is well tolerated and can lead to a significant drop in PP levels with no change in lesion size. There is insufficient data to suggest long-term benefit with octreotide therapy but it may be considered versus standard conservative management.http://dx.doi.org/10.1155/2019/9462942 |
| spellingShingle | Matthew H. Kemm Cory D. Manly Thanh D. Hoang Vinh Q. Mai Mohamed K. M. Shakir Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature Case Reports in Gastrointestinal Medicine |
| title | Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature |
| title_full | Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature |
| title_fullStr | Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature |
| title_full_unstemmed | Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature |
| title_short | Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature |
| title_sort | octreotide use in a patient with men 1 syndrome and multifocal pancreatic neuroendocrine tumors a case report and review of the literature |
| url | http://dx.doi.org/10.1155/2019/9462942 |
| work_keys_str_mv | AT matthewhkemm octreotideuseinapatientwithmen1syndromeandmultifocalpancreaticneuroendocrinetumorsacasereportandreviewoftheliterature AT corydmanly octreotideuseinapatientwithmen1syndromeandmultifocalpancreaticneuroendocrinetumorsacasereportandreviewoftheliterature AT thanhdhoang octreotideuseinapatientwithmen1syndromeandmultifocalpancreaticneuroendocrinetumorsacasereportandreviewoftheliterature AT vinhqmai octreotideuseinapatientwithmen1syndromeandmultifocalpancreaticneuroendocrinetumorsacasereportandreviewoftheliterature AT mohamedkmshakir octreotideuseinapatientwithmen1syndromeandmultifocalpancreaticneuroendocrinetumorsacasereportandreviewoftheliterature |